*** For details on how to be removed from this list visit the *** *** CCP4 home page http://www.ccp4.ac.uk ***
This has a description: http://deposit.rcsb.org/depoinfo/download/dp.pdf It says that renumbering is only done 'when necessary' or 'if it (the present numbering) will cause problems later'. An example is given: If the waters have only one chain ID, this chain ID can be removed through struct_biol_gen in ADIT . If waters in a particular entry have more than one chain ID and have similar numbering (for example, water chain A 1-100 and water chain B 1-100), the chain ID must be removed and the waters must be renumbered. -- Ian > -----Original Message----- > From: [EMAIL PROTECTED] [mailto:[EMAIL PROTECTED] On > Behalf Of Sue Roberts > Sent: 06 December 2006 16:00 > To: Gerard DVD Kleywegt > Cc: CCP4 Bulletin Board > Subject: Re: [ccp4bb]: refmac PDB header > > *** For details on how to be removed from this list visit the *** > *** CCP4 home page http://www.ccp4.ac.uk *** > > > Hello, > > Gerard, 'DVD", wrote the reply below. > > > > >> Would it be possible to make a lobby and get the PDB NOT > TO CHANGE > >> anything we don´t want to have changed in the structures that are > >> supposed to be > > > > alternatively - we could all follow the convention from the start > > So, how can we find out what this convention is? I just browsed the > depositor information at rcsb and didn't find any information on > solvent or ligand numbering. (Granted, I didn't do an exhaustive > search). > > Sue > > > > Disclaimer This communication is confidential and may contain privileged information intended solely for the named addressee(s). It may not be used or disclosed except for the purpose for which it has been sent. If you are not the intended recipient you must not review, use, disclose, copy, distribute or take any action in reliance upon it. If you have received this communication in error, please notify Astex Therapeutics Ltd by emailing [EMAIL PROTECTED] and destroy all copies of the message and any attached documents. Astex Therapeutics Ltd monitors, controls and protects all its messaging traffic in compliance with its corporate email policy. The Company accepts no liability or responsibility for any onward transmission or use of emails and attachments having left the Astex Therapeutics domain. Unless expressly stated, opinions in this message are those of the individual sender and not of Astex Therapeutics Ltd. The recipient should check this email and any attachments for the presence of computer viruses. Astex Therapeutics Ltd accepts no liability for damage caused by any virus transmitted by this email. E-mail is susceptible to data corruption, interception, unauthorized amendment, and tampering, Astex Therapeutics Ltd only send and receive e-mails on the basis that the Company is not liable for any such alteration or any consequences thereof.
